This episode of the VJNeurology podcast explores the evolving role of Bruton’s tyrosine kinase (BTK) inhibitors in the treatment of multiple sclerosis (MS), from the role of BTK in MS pathophysiology to the recent EU approval of tolebrutinib for secondary progressive MS without relapses. Experts discuss the pivotal Phase III HERCULES (NCT04411641) and GEMINI (NCT04410978) trial data supporting tolebrutinib, alongside findings from the Phase III FENtrepid trial (NCT04544449) of fenebrutinib, a non-covalent BTK inhibitor, in primary progressive MS.

Featuring Augusto Miravalle, MD, FAAN, Rush University Medical College, Chicago, IL, Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, Anthony Traboulsee, MD, University of British Columbia, Vancouver, Canada, and Amit Bar-Or, MD, FRCPC, University of Pennsylvania, Philadelphia, PA.